UNSPSC 51112508: Bendamustine hydrochloride

This classification denotes a nitrogen mustard compound with the molecular formula C16H21Cl2N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 981Y8SX18M, chemically known as 2-benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochloride but more generally known as bendamustine hydrochloride, which bears US NIH Compound Identifier 77082. The base compound, Bendamustine, most often comes in base and hydrochloride forms.

UNSPSC 51112508 Bendamustine hydrochloride, a Commodity code, identifies a chemotherapy agent used in cancer treatment protocols, particularly for chronic lymphocytic leukemia and certain lymphomas. State and local government procurement under this code reflects purchases by public health systems, state Medicaid agencies, correctional health departments, and public hospital networks seeking to stock this pharmaceutical for patient treatment and formulary compliance. The drug is sourced as a manufactured pharmaceutical product, typically in vial or powder form requiring reconstitution, and procurement focuses on securing reliable supply at competitive pricing through standard pharmaceutical distribution channels or direct manufacturer agreements.

The source provided contains no recent state and local contract opportunities tagged to this code, preventing characterization of issuing-body concentration, geographic activity patterns, or representative recent solicitations. Without posted RFP, RFQ, IFB, or ITB records under this commodity code, no current procurement signal can be assessed.